NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has taken a major strategic step by acquiring StemSmart™, a globally patented and clinically validated stem cell platform. This acquisition adds a powerful, next-generation therapeutic capability to the company’s focus on neuroimmune and inflammatory diseases.

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), the recognised global developer of allogeneic cellular medicines, has released an important update that reflects both regulatory momentum and commercial progress across its core programs in inflammatory diseases.